Lv11
18 积分 2022-11-22 加入
Topical Drug Candidate Selection Criteria and Cascade
1小时前
待确认
Nemolizumab for the treatment of atopic dermatitis
2天前
已完结
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
2天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
8天前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
10天前
已完结
Research progress in OX40/OX40L in allergic diseases
15天前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
15天前
已完结
345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis
15天前
已完结
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics
1个月前
已完结
Vitiligo
2个月前
已完结
皖公网安备34019202002308
